Poster pour le European Congress of Clinical Microbiology and Infectious Diseases 2023

17 avril 2023

The SAIVE Trial, Post-Exposure use of ivermectin in Covid-19 prevention: Efficacy and Safety Results

INTRODUCTION
Ivermectin (IVM) is a well-known drug currently used to treat several parasitic diseases. It has a proven safety profile over many decades of exposure. It is one of the several drugs explored for its potential therapeutic and preventive role against SARS-CoV-2 infection as previous studies had reported its antiviral effects on both RNA and DNA viruses1,2. Caly et al. demonstrated that a single dose of IVM could control the in vitro replication of SARS-CoV-23. Several mechanisms of action have been suggested for its effect on SARS-CoV-24. Those mechanisms could lead to an efficient SARS-CoV-2 prevention, independently of virus mutations5. Post-exposure prophylaxis (PEP) is a method of preventing SARS-CoV-2 infection after a known exposure to the virus that may limit the spread of infection.

Download Poster

Session en français

Mardi 19 décembre, 18h30 : Présentation des résultats du premier semestre de l'année fiscale 2023-24

English session

Tuesday, December 19, 6:30 pm: Half-year earnings call (April 1st - September 30th)

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
Ce champ n’est utilisé qu’à des fins de validation et devrait rester inchangé.

CONTACT

  • Ce champ n’est utilisé qu’à des fins de validation et devrait rester inchangé.